Abubakar Umar Anka

Abubakar Umar Anka

Auto-generated profile, based on publicly available information

Abubakar Umar Anka

Department of Medical Laboratory Science College of Medical Sciences Ahmadu Bello University Zaria Nigeria

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2020 in Scandinavian Journal of Immunology
Verified
Journal Article
Open access
PDF file
AAAbubakar Umar Anka
Abubakar Umar Anka
MTMohammed Ibrahim Tahir
Mohammed Ibrahim Tahir
SASharafudeen Dahiru Abubakar
Sharafudeen Dahiru Abubakar
MAMohamed Alsabbagh
Mohamed Alsabbagh
ZZZeineb Zian
Zeineb Zian
GAGholamreza Azizi
Gholamreza Azizi
SARS‐CoV‐2 is a novel human coronavirus responsible for the Coronavirus disease 2019 (COVID‐19) pandemic. Pneumonia and acute respiratory distress syndrome are the major complications of COVID‐19. SARS‐CoV‐2 infection can activate innate and adaptive immune responses and result in massive inflammatory responses later in the disease. These uncontrolled inflammatory responses may lead to local and systemic tissue damage. In patients with severe COVID‐19, eosinopenia and lymphopenia with a severe reduction in the frequency of CD4+ and CD8+ T cells, B cells and natural killer (NK) cells are a common feature. COVID‐19 severity hinges on the development of cytokine storm characterized by elevated serum levels of pro‐inflammatory cytokines. Moreover, IgG‐, IgM‐ and IgA‐specific antibodies against SARS‐CoV‐2 can be detected in most patients, along with the viral RNA, forming the basis for assays that aid in patient diagnosis. Elucidating the immunopathological outcomes due to COVID‐19 could provide potential targets for immunotherapy and are important for choosing the best clinical management by consultants. Currently, along with standard supportive care, therapeutic approaches to COVID‐19 treatment involve the use of antiviral agents that interfere with the SARS‐CoV‐2 lifecycle to prevent further viral replication and utilizing immunomodulators to dampen the immune system in order to prevent cytokine storm and tissue damage. While current therapeutic options vary in efficacy, there are several molecules that were either shown to be effective against other viruses such as HIV or show promise in vitro that could be added to the growing arsenal of agents used to control COVID‐19 severity and spread.

11 June 2020 in Proceedings of Singapore Healthcare
Verified
Journal Article
Open access
PDF file
IAIdris Nasir Abdullahi
Idris Nasir Abdullahi
AAAbubakar Umar Anka
Abubakar Umar Anka
PGPeter Elisha Ghamba
Peter Elisha Ghamba
NONkechi Blessing Onukegbe
Nkechi Blessing Onukegbe
DADele Ohinoyi Amadu
Dele Ohinoyi Amadu
MSMatthew Oluwafemi Salami
Matthew Oluwafemi Salami
Lassa virus (LASV) has increasingly been recognised as a significant public-health pathogen transmitted by rodents. LASV infection leads to life-threatening Lassa fever, which has high potential for severe morbidity and mortality. There have been several scientific efforts to understand the genomics and ecological epidemiology of Lassa. However, very limited studies have focused on the short- and long-term impacts of environmental factors, human behaviours and rodent activities on LASV transmission dynamics and control. Recently, a very plausible and ideal way to address the Lassa epidemic has been considered through the One Health approach. The One Health system of intervention is capable of providing better and comprehensive information necessary to address the complex interplay between human, ecological, and environmental determinants of LASV transmission, persistence and re-emergence. Thus, the aim of this article was to review critically the impacts of various environmental factors on rodent infestations, LASV transmission and how human activities contribute to the persistence of Lassa with regard to exploring how they could be harnessed for better understanding of Lassa prevention and control through a concerted One Health approach.

1 January 2020 in The Eurasian Journal of Medicine
Verified
Journal Article
Open access
IAIdris Nasir Abdullahi
Idris Nasir Abdullahi
AEAnthony Emeribe
Anthony Emeribe
HAHafeez Aderinsayo Adekola
Hafeez Aderinsayo Adekola
HMHabiba Yahaya Muhammad
Habiba Yahaya Muhammad
AAAbdurrahman El-Fulaty Ahmad
Abdurrahman El-Fulaty Ahmad
ABAdamu Babayo
Adamu Babayo
Objective: T-helper cells (Th)-1& -2 cytokines homeostasis control or predict clinical outcome of infected persons, especially those with HIV /AIDS. This case-control study evaluated the leucocytes differentials, TNF-alpha, interleukin (IL)-2 and -10 levels among HIV infected persons with serological evidence of leishmaniasis attending University of Abuja Teaching Hospital, Nigeria Materials and Methods: Blood samples from 28 HIV infected persons who had Leishmania donovani rK39 and Immunoglobulin-G (IgG) positive (group 1), 30 age- & -sex matched HIV infected persons without Leishmania antibodies (group 2) and 30 apparently healthy persons without HIV and Leishmania antibodies (group 3). Full blood counts, TNF alpha, IL-2 and -10 levels were analyzed using automated hematology analyzer and ELISA, respectively. Structured questionnaires were used to collate biodata and clinical presentations of participants. Results: Ten (35.7%) participants in group 1 were on ART, 15 (50%) in group 2 were on ART, while group 3 were ART naïve. There were significantly higher values in basophil (4.4±2.5%) and eosinophil counts (12.9±3.8%) in HIV/leishmania coinfected persons (p<0.005). However, other white cells subpopulation was significantly lower in HIV/leishmania co-infected participants (p<0.05). There was significantly reduced CD4+ T cell counts ([119±26 versus 348±63 versus 605±116 cells/mm3]), TNF-alpha ([36.82±8.21 versus 64.67±12.54 versus 254.98±65.59 pg/mL]) and IL-2 levels ([142.14±20.91 versus 507.6±84.42 versus 486.62±167.87 pg/mL]) among HIV/Leishmania co-infected participants compared to group 2 and group 3 participants, respectively. However, higher IL-10 level (80.35±14.57 pg/mL) was found in HIV/Leishmania co-infected participants as opposed to the HIV monoinfected (62.2±10.43 pg/mL) and apparently healthy persons (23.97±4.88 pg/mL) (p<0.001). Conclusion: Eosinophil, basophil counts and serum IL-10 level were high in HIV/Leishmania coinfected persons, demonstrating parasite-induced hypersensitivity and immunosuppression. Cite this article as: Abdullahi IN, Emeribe AU, Adekola HA, et al. Leucocytes and Th-associated Cytokine Profile of HIV-Leishmaniasis Co-Infected Persons Attending Abuja Teaching Hospital, Nigeria. Eurasian J Med 2020; 52(3): 271-6.

30 January 2020 in Journal of Medical Science
Verified
Journal Article
Open access
IAIdris Nasir Abdullahi
Idris Nasir Abdullahi
AEAnthony Uchenna Emeribe
Anthony Uchenna Emeribe
HAHafeez Aderinsayo Adekola
Hafeez Aderinsayo Adekola
HMHabiba Yahaya Muhammad
Habiba Yahaya Muhammad
AAAbdurrahman El-Fulaty Ahmad
Abdurrahman El-Fulaty Ahmad
ABAdamu Babayo
Adamu Babayo
Introduction. T helper cells (Th)-1 and -2 cytokines homeostasis control or predict clinical outcome of infected persons, especially those with HIV/AIDS. This case-control study evaluated the leucocyte differentials, TNF-α, IL-2 and -10 levels, among HIV-infected persons with serological evidence of leishmaniasis attending the University of Abuja Teaching Hospital, Nigeria. Material and Methods. This study involved blood samples from 28 HIV-infectedwith Leishmania donovani rK39 and IgG positive (group 1), 30 age- and sex-matched HIV-infected individuals without Leishmania antibodies (group 2) and 30 apparently healthy persons without HIV and Leishmania antibodies (group 3). Full blood counts, TNF-α, IL-2 and IL-10 levels were analysed using an automated haematology analyser and ELISA, respectively. Structured questionnaires were used to collate biochemical and clinical data from participants. Results. Ten (35.7%) participants in group 1 were on ART, 15 (50%) in group 2 were on ART, while group 3 were ART naïve. There were significantly higher values in basophil (4.4 ± 2.5%) and eosinophil counts (12.9 ± 3.8%) in HIV/Leishmania coinfected persons (p˂0.005), whereas other white cell subpopulations were significantly lower in the HIV/Leishmania coinfected participants (p˂0.05). There were significantly reduced CD4+ T cell counts (119 ± 26 vs 348 ± 63 vs 605 ± 116 cells/mm3), TNF-α (36.82 ± 8.21 vs 64.67 ± 12.54 vs 254.98 ± 65.59 pg/mL) and IL-2 levels (142.14 ± 20.91 vs 507.6 ± 84.42 vs 486.62 ± 167.87 pg/mL) among HIV/Leishmania coinfected participants compared to group 2 and group 3 participants, respectively. However, higher IL-10 levels (80.35 ± 14.57 pg/mL) were detected in HIV/Leishmania coinfected participants compared to the HIV mono-infected (62.2 ± 10.43 pg/mL) and apparently healthy persons (23.97 ± 4.88 pg/mL; p˂0.001). Conclusion. Eosinophil and basophil counts, and serum IL-10 level were high in HIV/Leishmania coinfected patients demonstrating parasite-induced hypersensitivity and immunosuppression.